Skip to main content
. Author manuscript; available in PMC: 2008 Dec 22.
Published in final edited form as: Ann Intern Med. 1999 Dec 7;131(11):813–821. doi: 10.7326/0003-4819-131-11-199912070-00003

Table 2. Protease Mutation Patterns at Baseline and Response to Saquinavir–Ritonavir Combination Therapy*.

Major Protease Mutations at Baseline† Patients Median Additional Baseline Mutations (Range) Median Baseline CD4 Count CD4 Count at 12 Weeks: Median Change from Baseline Median Baseline Plasma HIV RNA Level Follow-up Plasma HIV RNA Level during Saquinavir–Ritonavir Therapy
Protease Reverse Transcriptase Change from Baseline at 4 Weeks Change from Baseline at 12 Weeks <500 copies/mL <50 copies/mL
graphic file with name nihms65122t1.jpg ×109 cells/L graphic file with name nihms65122t2.jpg n (%)
None 11 5 (1–7) 10 (0–17) 240 60 4.7 −1.8 −2.4 9 (82) 6 (55)
D30N 7 4 (3–9) 11 (9–14) 500 55 3.6 −2.0 −1.8 7 (100) 3 (43)
At codon 46, 82, or 84 3 11 (8–11) 10 (9–11) 200 50 4.6 −1.7 −1.8 2 (67) 1 (33)
L90M 6 6 (4–7) 10 (8–19) 345 5 4.6 −1.5 −1.2 2 (33) 0
Any two mutations 10 7 (0–10) 12 (4–16) 140 40 5.0 −0.9 −0.5 2 (20) 0
Three or more mutations 17 7 (2–10) 14 (7–24) 170 0 5.0 −0.2 0.0 0 0
*

Response defined as <500 or <50 copies/mL by 12 weeks.

†

Based on “major” protease mutations, defined as those at codons 30, 46, 48, 54, 82, 84, and 90 (see Methods section).